Frontiers Science Center for Disease-related Molecular Network, Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, 610041, China.
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, China.
J Pharm Biomed Anal. 2021 Sep 5;203:114208. doi: 10.1016/j.jpba.2021.114208. Epub 2021 Jun 15.
With continuously increased scan rate and sensitivity, high resolution mass spectrometry (HRMS) allows for both reliable targeted analysis (e.g., parallel reaction monitoring, PRM) and a global overview for discovery-based untargeted profiling (e.g., data dependent acquisition, DDA) to be performed. Based on previous study on PRM for large scale targeted metabolomics quantification, we developed an innovative method merged targeted and untargeted approaches in a single run. In our workflow, the scheduled PRM for targeted analysis of amino acids and derivatives combined with the full scan was acquired in every sample injection by hydrophilic interaction liquid chromatography tandem quadrupole-Orbitrap high resolution mass spectrometry (HILIC-Q-Orbitrap HRMS). The identification of metabolic features from full scan was further performed with DDA methodology on grouped quality control (QC) samples and matched with available database. Specifically, 20 amino acids and 40 derivatives were selected for targeted analysis with optimal chromatographic separation and PRM parameters. All isomers within the selected metabolites were totally separated in the robust HILIC condition. 36 of selected metabolites were well-detected and showed a good linearity and reproducibility in NIST SRM 1950 plasma. Moreover, the absolute quantification performance of targeted PRM method was systematically validated using 10 amino acids with the corresponding stable isotope-labeled internal standards (SIL-IS). Finally, the newly developed method was successfully applied to analysis of the plasma samples from patients of pancreatic benign tumor and pancreatic cancer. The significant reduction of circulating amino acids in patients with pancreatic malignancy was confirmed by targeted PRM method and other amino acids modifications as well as polar metabolites were identified with untargeted profiling. Therefore, we have established a workflow that combines specifically and reliably targeted PRM method as well as broad-coverage untargeted profiling, which provides an innovative strategy for basic and clinical metabolomics study.
随着扫描速度和灵敏度的不断提高,高分辨率质谱(HRMS)既可以进行可靠的靶向分析(例如平行反应监测,PRM),也可以进行基于发现的非靶向分析(例如数据依赖采集,DDA)。基于之前关于大规模靶向代谢组学定量分析的 PRM 研究,我们开发了一种创新的方法,可在单个运行中合并靶向和非靶向方法。在我们的工作流程中,针对氨基酸和衍生物的靶向分析的预定 PRM 与全扫描相结合,通过亲水相互作用液相色谱串联四极杆-Orbitrap 高分辨率质谱(HILIC-Q-Orbitrap HRMS)在每个样品进样中采集。通过 DDA 方法对分组质控(QC)样品进行代谢特征的鉴定,并与可用数据库匹配。具体来说,选择 20 种氨基酸和 40 种衍生物进行靶向分析,具有最佳的色谱分离和 PRM 参数。在稳健的 HILIC 条件下,所选代谢物的所有异构体完全分离。在所选择的代谢物中,有 36 种检测良好,在 NIST SRM 1950 血浆中具有良好的线性和重现性。此外,使用 10 种具有相应稳定同位素标记内标(SIL-IS)的氨基酸对靶向 PRM 方法的绝对定量性能进行了系统验证。最后,该新方法成功应用于胰腺良性肿瘤和胰腺癌患者的血浆样品分析。通过靶向 PRM 方法和其他氨基酸修饰以及鉴定极性代谢物,证实了胰腺恶性肿瘤患者循环氨基酸显著减少。因此,我们建立了一种工作流程,该流程结合了特异性和可靠的靶向 PRM 方法以及广泛覆盖的非靶向分析,为基础和临床代谢组学研究提供了一种创新策略。